About Saniona 

Saniona is an epilepsy focused clinical-stage biopharmaceutical company engaged in the discovery and development of medicines modulating ion channels. Saniona’s epilepsy pipeline includes the Phase 2 ready asset SAN711 positioned for treatment of absence seizures, the preclinical development compound SAN2219 for acute repetitive seizures and the drug-discovery program on Kv7 modulators for refractory focal onset seizures. Outside epilepsy Saniona has three clinical programs, which are positioned for partnering. The most advanced candidate, tesofensine, has progressed towards regulatory approval for obesity in Mexico by Saniona’s partner Medix, whereas Tesomet™ is ready for Phase 2b for rare eating disorders, and SAN903 is ready for Phase 1 for inflammatory bowel disease. Saniona has research and development partnerships with Boehringer Ingelheim GmbH, Productos Medix, S.A de S.V, AstronauTx Limited and Cephagenix ApS. Saniona is based in Copenhagen, and listed on Nasdaq Stockholm Small Cap (OMX: SANION).  

Press release 

The case 

• Clinical-stage biopharmaceutical company focused on epilepsy – leader in ion channel drug discovery and development. 
• Cutting-edge proprietary ion channel drug discovery engine continuously generating new drug candidates with substantial potential.
  • SAN711 (epilepsy), SAN903 (inflammatory and fibrotic diseases), SAN2219 (epilepsy), Kv7 2/3, Migraine program (Cephagenix partnership), Schizophrenia program (Boehringer Ingelheim partnership), Alzheimer’s program (AstronauTx partnership). 
• Saniona’s asset Tesofensine is targeting market launch 2024, together with market leader Medix, targeting the Mexican USD 190 million obesity market.
  
• Through successful spinouts, partnerships, and licensing agreements Saniona has received approx. SEK 400 million with future upside potential preserved through milestones and royalties from companies such as Janssen, Pfizer, Boehringer Ingelheim, AstronauTx and Medix. 

Website: https://saniona.com/investors/